Paper41468356
Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.
Deshmukh MS and 8 others. Cancer Prev Res (Phila), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ. Papers, record 41468356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41468356
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Factors Associated with Low-Dose Tamoxifen Use among Women with Atypical Hyperplasia or Lobular or Ductal Carcinoma In Situ.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tamoxifen | Major topic |
| Breast Neoplasms | Major topic |
| Carcinoma, Intraductal, Noninfiltrating | Major topic |
| Antineoplastic Agents, Hormonal | Major topic |
| Carcinoma, Lobular | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Aged | |
| Hyperplasia | |
| Adult | |
| Selective Estrogen Receptor Modulators | |
| Aromatase Inhibitors | |
| Retrospective Studies | |
| Follow-Up Studies |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA013696 | NCI NIH HHS | United States | P30CA013696 | PubMed | NIH RePORTER |
| R01 CA226060 | NCI NIH HHS | United States | R01CA226060 | PubMed | NIH RePORTER |
| R01 CA293927 | NCI NIH HHS | United States | R01CA293927 | PubMed | NIH RePORTER |
| UL1 TR000040 | NCATS NIH HHS | United States | UL1TR000040 | PubMed | NIH RePORTER |
| R01CA293927 | National Cancer Institute (NCI) | R01CA293927 | PubMed | NIH RePORTER | |
| R01CA226060 | National Cancer Institute (NCI) | R01CA226060 | PubMed | NIH RePORTER | |
| P30CA013696 | National Cancer Institute (NCI) | P30CA013696 | PubMed | NIH RePORTER | |
| UL1TR000040 | National Center for Advancing Translational Sciences (NCATS) | UL1TR000040 | PubMed | NIH RePORTER |
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9747868 | Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. | J Natl Cancer Inst | 1998 | https://conductscience.org/library/papers/9747868 | PubMed |
| 2 | 21537936 | Second events following ductal carcinoma in situ of the breast: a register-based cohort study. | Breast Cancer Res Treat | 2011 | https://conductscience.org/library/papers/21537936 | PubMed |
| 3 | 39837695 | Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. | Clin Breast Cancer | 2025 | https://conductscience.org/library/papers/39837695 | PubMed |
| 4 | 39623980 | Selecting the Right Dose to Move Breast Cancer Prevention Forward. | Cancer Prev Res (Phila) | 2024 | https://conductscience.org/library/papers/39623980 | PubMed |
| 5 | 20458026 | Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20458026 | PubMed |
| 6 | 30815800 | Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor. | Ann Surg Oncol | 2019 | https://conductscience.org/library/papers/30815800 | PubMed |
| 7 | 26615179 | Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. | J Natl Cancer Inst | 2016 | https://conductscience.org/library/papers/26615179 | PubMed |
| 8 | 35378642 | Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. | Breast Cancer Res Treat | 2022 | https://conductscience.org/library/papers/35378642 | PubMed |
| 9 | 31479306 | Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/31479306 | PubMed |
| 10 | 38704119 | Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. | Contemp Clin Trials | 2024 | https://conductscience.org/library/papers/38704119 | PubMed |
| 11 | 29061559 | A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene. | Cancer Prev Res (Phila) | 2018 | https://conductscience.org/library/papers/29061559 | PubMed |
| 12 | 25993215 | Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. | Am Soc Clin Oncol Educ Book | 2015 | https://conductscience.org/library/papers/25993215 | PubMed |
| 13 | 33863327 | Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women's risk-reduction experiences. | BMC Womens Health | 2021 | https://conductscience.org/library/papers/33863327 | PubMed |
| 14 | 39377401 | Improved Uptake and Adherence to Risk-Reducing Medication with the Use of Low-Dose Tamoxifen in Patients at High Risk for Breast Cancer. | Cancer Prev Res (Phila) | 2024 | https://conductscience.org/library/papers/39377401 | PubMed |
| 15 | 28611039 | Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. | Cancer Prev Res (Phila) | 2017 | https://conductscience.org/library/papers/28611039 | PubMed |
| 16 | 16110014 | Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16110014 | PubMed |
| 17 | 30973790 | Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30973790 | PubMed |
| 18 | 27381855 | Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. | Int J Cancer | 2016 | https://conductscience.org/library/papers/27381855 | PubMed |
| 19 | 36095296 | Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/36095296 | PubMed |
| 20 | 36917758 | Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36917758 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42391096 | Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/42391096 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41468356
GET https://conductscience.org/api/papers/v1/41468356/references?page=2